cytarabine

Type: Keyphrase
Name: cytarabine
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

BI’s Volasertib Is an Orphan Drug in the U.S. and EU

U.S. and EU regulators have both determined that Boehringer Ingelheim’s volasertib for acute myeloid leukemia is an orphan drug, the German drugmaker said Thursday. The designation, which is granted to drugs that serve patient populations of 200,000 or ... [Published FDA News - Apr 18 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Recent Studies from University of Ulsan Add New Data to Stem Cells

By a News Reporter-Staff News Editor at Biotech Week -- Research findings on Stem Cell Research are discussed in a new report. According to news originating from Seoul, South Korea , by NewsRx correspondents, research stated, "BackgroundHigh-dose chemotherapy ... [Published HispanicBusiness.com - Apr 17 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Treatment Landscape for Mantle Cell Lymphoma Continues to Evolve

Andre Goy, MDLymphoma expert Andre Goy, MD, discussed the emerging landscape of mantle cell lymphoma (MCL) therapy at the 18th Annual International Congress on Hematologic Malignancies. Several novel agents are being tested in clinical trials for MCL. ... [Published OncLive - Apr 16 2014]
First reported Apr 12 2014 - Updated Apr 12 2014 - 1 reports

‘Double-Hit’ Lymphomas a Challenge for the Oncologist

Daniel J. Landsburg, MDIt’s the worst of both worlds…. You have Bcl2 protein expression, which renders cells antiapoptotic and more difficult to kill, and a MYC rearrangement that makes cells more proliferative. You can kill MYC-positive cells, but if ... [Published The ASCO Post - Apr 12 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 2 reports

Sunesis Announces Presentation of Positive Results From Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS

Data Presented at AACR 2014 Annual MeetingCompany to Host Conference Call Today at 8:00 AM Pacific TimeSOUTH SAN FRANCISCO, Calif., April 8, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of results ... [Published Virtual Strategy Magazine - Apr 08 2014]
First reported Apr 07 2014 - Updated Apr 07 2014 - 2 reports

Ambit Initiates Phase 2 Trial of Quizartinib Combo in AML MDS

Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology , autoimmune and inflammatory disease, announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored ... [Published BioPortfolio - Apr 07 2014]
First reported Apr 06 2014 - Updated Apr 06 2014 - 1 reports

MicroRNA-155 as an inducer of apoptosis and cell differentiation in Acute Myeloid Leukaemia

ResearchCatalina A Palma , Dima Al Sheikha , Teck Khai Lim , Adam Bryant , Thi Thanh Vu , Vivek Jayaswal and David D MaMolecular Cancer 2014, 13 :79doi:10.1186/1476-4598-13-79Published: 5 April 2014Abstract (provisional) BackgroundAcute myeloid leukaemia ... [Published MOLECULAR CANCER - Apr 06 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 2 reports

IMRIS iMRI and ClearPoint Neuro Intervention System utilized for first pediatric laser ablation neurosurgery at Cook Children's Medical Center

Latest joint application of these two technologies provides direct, intraoperative visualization during surgery to treat a childhood brain tumorMINNEAPOLIS, MN and IRVINE, CA, April 3, 2014 /PRNewswire/ - IMRIS Inc. (NASDAQ:IMRS) (TSX: IM) ("IMRIS") and ... [Published Nasdaq - Apr 03 2014]
First reported Apr 02 2014 - Updated Apr 02 2014 - 2 reports

Sunesis Announces MD Anderson Sponsored Trial of Vosaroxin in AML and High-Risk MDS Poster to be Presented …

(GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. ( SNSS ) today announced that updated data from the ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored trial of vosaroxin in combination with decitabine in older patients with previously ... [Published Yahoo! Finance - Apr 02 2014]
First reported Mar 26 2014 - Updated Mar 26 2014 - 1 reports

Research Data from Goethe-University Update Understanding of Acute Myeloid Leukemia

By a News Reporter-Staff News Editor at Biotech Week -- Data detailed on Oncology have been presented. According to news reporting originating in Frankfurt, Germany , by NewsRx journalists, research stated, "The prognosis for patients with acute myeloid ... [Published 4 Traders - Mar 26 2014]
First reported Mar 24 2014 - Updated Mar 25 2014 - 2 reports

Celator Pharmaceuticals Announces Business Update and Fourth Quarter and Full Year 2013 Financial Results

"2013 was a transformative year for Celator, attaining important milestones as we continue to leverage our CombiPlex(R) platform to introduce an entirely new medical standard for combining cancer therapies," said Scott Jackson , chief executive officer ... [Published HispanicBusiness.com - Mar 25 2014]
First reported Mar 11 2014 - Updated Mar 12 2014 - 2 reports

Selvita will present new data from its PIM/FLT3 and MNK1/2 oncology programs during AACR Annual Meeting 2014

Selvita will present two posters:• The poster entitled "Repression of tumor survival pathways by novel and selective inhibitors of MNK1 and MNK2 kinases in glioblastoma and colorectal cancer" will be presented at the session on Sunday, April 6th, 2014 ... [Published 4 Traders - Mar 12 2014]
Entities: Kinase, Oncology, malignancy

Quotes

...According to news originating from Seoul, South Korea , by NewsRx correspondents, research stated, "BackgroundHigh-dose chemotherapy supported by autologous stem cell transplantation is an effective treatment for patients with relapsed or refractory non-Hodgkin's lymphomas (NHLs) and fit patients with multiple myeloma (MM). However, failure rates of hematopoietic stem cell mobilization are estimated to be between 5 and 30%, respectively."
...advancement of Lorus lead agent LOR-253 in hematologic cancers," said William G Rice, Ph D , Chairman President and ChiefChief Executive Officer. "With the closing of a $25 million financing announced, we expect to have the capital needed to execute our developmental milestones for the foreseeable future."
"With medical advances, children requiring bone marrow transplant for various hematologic malignancies, solid tumors, and nonmalignant diseases have increasing survival rates" said first author Julie Calderwood, MD, senior ophthalmology resident at the University of Tennessee Health Science Center in Memphis
...said Farhad Ravandi, M D , Professor of Medicine, Department of Leukemia, University of Texas MD Anderson Cancer Center, and a study investigator. "Emerging outcomes from this trial suggest that vosaroxin and decitabine hold meaningful promise as a potential new combination treatment option for this population. The high number of complete remissions with good tolerability are highly encouraging and make this trial a designated priority for our center."

More Content

All (56) | News (52) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (3)
sort by: Date | Relevance
BI’s Volasertib Is an Orphan Drug in the U.S. a... [Published FDA News - Apr 18 2014]
Volasertib Granted ‘Orphan Drug’ Designation fo... [Published P&T Community - Apr 17 2014]
Volasertib, Boehringer Ingelheim´s investigatio... [Published Boehringer Ingelheim - Apr 17 2014]
Directing Treatment by Molecular Subtype in Dif... [Published Cancernetwork.com - Apr 17 2014]
Recent Studies from University of Ulsan Add New... [Published HispanicBusiness.com - Apr 17 2014]
Treatment Landscape for Mantle Cell Lymphoma Co... [Published OncLive - Apr 16 2014]
Lorus Therapeutics Posts Third Quarter Results ... [Published Individual.com - Apr 16 2014]
Why Childhood Cancer Survival Rates Have Increased [Published Daily Rx - Apr 15 2014]
Variants of humanized immunomodulatory monoclon... [Published PharmCast - Apr 15 2014]
Lorus announces encouraging preclinical data fr... [Published Individual.com - Apr 14 2014]
‘Double-Hit’ Lymphomas a Challenge for the Onco... [Published The ASCO Post - Apr 12 2014]
Ocular Effects Common After Childhood Bone Marr... [Published American Journal of Public Health - Apr 11 2014]
Targeting of bone marrow neovasculature [Published PharmCast - Apr 11 2014]
GlycoMimetics: A Promising Sickle Cell Disease ... [Published Seeking Alpha - Apr 10 2014]
Sunesis announces positive results from Phase I... [Published Individual.com - Apr 10 2014]
Tumor-initiating cells and methods of use [Published PharmCast - Apr 09 2014]
Lorus Therapeutics : Presents Preclinical Data ... [Published 4 Traders - Apr 08 2014]
Sunesis Announces Presentation of Positive Resu... [Published Virtual Strategy Magazine - Apr 08 2014]
Sunesis Announces Presentation of Positive Resu... [Published Benzinga.com - Apr 08 2014]
IMRIS iMRI and ClearPoint Neuro platform used f... [Published MedicalPhysicsWeb - Apr 08 2014]
Ambit Initiates Phase 2 Trial of Quizartinib Co... [Published BioPortfolio - Apr 07 2014]
Ambit Announces Initiation Of Phase 2 Cohort In... [Published Nasdaq - Apr 07 2014]
MicroRNA-155 as an inducer of apoptosis and cel... [Published MOLECULAR CANCER - Apr 06 2014]
IMRIS iMRI and ClearPoint Neuro Intervention Sy... [Published Nasdaq - Apr 03 2014]
MRI Interventions to Exhibit its ClearPoint Neu... [Published I Stock Analyst - Apr 03 2014]
IMRIS iMRI and ClearPoint Neuro Intervention Sy... [Published Barchart - Apr 03 2014]
Sunesis Announces MD Anderson Sponsored Trial o... [Published Yahoo! Finance - Apr 02 2014]
Sunesis Announces MD Anderson Sponsored Trial o... [Published Benzinga.com - Apr 02 2014]
Celator Begins Clinical Study of CPX-351 in Hig... [Published Azonano - Mar 28 2014]
Research Data from Goethe-University Update Und... [Published 4 Traders - Mar 26 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
CYTARABINE Injection [Mylan Institutional LLC ] [Published DailyMed Drug Label Updates for the last seven ... - Feb 14 2014]
Updated Date: Feb 14, 2014 EST ...
1

Press Releases

sort by: Date | Relevance
Celator(R) Pharmaceuticals Reaches 50% Enrollme... [Published GlobeNewswire: Acquisitions News - Jan 09 2014]
Celator(R) Pharmaceuticals Announces Positive D... [Published GlobeNewswire: Advertising News - Dec 12 2013]
Sunesis Pharmaceuticals Announces Initiation of... [Published GlobeNewswire: Acquisitions News - Oct 30 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.